ClinicalTrials.gg
CompletedNCT05696847Updated Aug 26, 2025Results posted

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

A Phase 1 interventional study of Tirzepatide and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
92nd of 104
28 · median 69
Started
2023
with 7 others
Phase 1
12 of 104
5 open now
Registered
15th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 92nd largest by enrollment, is one of 8 that started in 2023, is one of 12 in phase 1, and was the 15th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Pediatrics
  • Obesity
  • Chronic weight management
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants with (BMI) ≥ the 95th percentile for age and sex
  • Have failed to achieve adequate weight loss through lifestyle modification in the investigator's opinion
  • Female participants only: Determined as prepubertal Tanner Stage 1.

Exclusion criteria

Exclusion Criteria:

  • Change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records
  • Have obesity induced by other endocrinologic disorders (for example, Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity
  • Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis; or have other GI disorders
  • Have a known gastric emptying, have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surger, or have endoscopic or device-based therapy for obesity or have had device removal within the last 6 months.
  • Have confirmed type 1 or type 2 diabetes mellitus
  • Have a history or current cerebrovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the IP; or may interfere with the interpretation of data
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Placebo comparator
    Cohort 1: Placebo (BW >=50 kg)

    Participants in this cohort had a screening body weight (BW) of at least 50 kilograms (kg) received placebo administered subcutaneously (SC) once weekly (QW) during Weeks 1 to 8.

    Drug: Placebo

  • Experimental
    Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)

    Participants in this cohort had a screening body weight of at least 50 kg received 2.5 milligrams (mg) tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8.

    Drug: Tirzepatide

  • Placebo comparator
    Cohort 2: Placebo (BW <50 kg)

    Participants in this cohort had a screening body weight less than 50 kg received placebo administered SC QW during Weeks 1 to 8.

    Drug: Placebo

  • Experimental
    Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)

    Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8.

    Drug: Tirzepatide

  • Placebo comparator
    Cohort 3: Placebo (BW 40 to 60 kg)

    Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received placebo administered SC QW during Weeks 1 to 8.

    Drug: Placebo

  • Experimental
    Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)

    Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8.

    Drug: Tirzepatide

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)

    Percentage of participants with TEAEs and SAEs were reported here. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.

    Time frame: Baseline through Week 14

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide

    PK: AUC0-tau of tirzepatide was reported.

    Time frame: Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.

  2. PK: Maximum Concentration (Cmax) of Tirzepatide

    PK: Cmax of tirzepatide

    Time frame: Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.

07

Results

Posted Aug 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)
Started362737
Received at least one dose of study drug262737
Completed252636
Not completed110101
Withdrew: Withdrawal by subject100000
Withdrew: Withdrawal by parent/guardian010000
Withdrew: Adverse event000001
Withdrew: Sponsor decision000100

Outcome measures

PrimaryPercentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)

Percentage of participants with TEAEs and SAEs were reported here. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.

Time frame:
Baseline through Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
Percentage of participantsCohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)
TEAE0.083.30.085.733.3100.0
SAE0.00.00.00.00.00.0
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide

PK: AUC0-tau of tirzepatide was reported.

Time frame:
Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.
Reported as:
Mean · nanogram *hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide
nanogram *hour per milliliter (ng*h/mL)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide105000 ± 3310080800 ± 9580156000 ± 22500
SecondaryPK: Maximum Concentration (Cmax) of Tirzepatide

PK: Cmax of tirzepatide

Time frame:
Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.
Reported as:
Mean · nanograms per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Tirzepatide
nanograms per milliliter (ng/mL)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)
PK: Maximum Concentration (Cmax) of Tirzepatide884 ± 243674 ± 63.81280 ± 194

Adverse events

Collected over Baseline Up To 14 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Placebo (BW >=50 kg)0/2 (0%)0/2 (0%)0/2 (0%)
Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 2: Placebo (BW <50 kg)0/2 (0%)0/2 (0%)0/2 (0%)
Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)0/7 (0%)0/7 (0%)6/7 (85.7%)
Cohort 3: Placebo (BW 40 to 60 kg)0/3 (0%)0/3 (0%)1/3 (33.3%)
Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)0/7 (0%)0/7 (0%)7/7 (100%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventCohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)
VomitingGastrointestinal disorders0/21/60/21/70/36/7
NauseaGastrointestinal disorders0/23/60/22/70/35/7
Abdominal painGastrointestinal disorders0/20/60/21/71/34/7
Decreased appetiteMetabolism and nutrition disorders0/23/60/21/70/31/7
DiarrhoeaGastrointestinal disorders0/21/60/20/70/33/7
ConstipationGastrointestinal disorders0/22/60/20/71/30/7
PyrexiaGeneral disorders0/20/60/21/71/30/7
PneumoniaInfections and infestations0/20/60/20/71/30/7
HeadacheNervous system disorders0/20/60/21/71/30/7
DyspepsiaGastrointestinal disorders0/20/60/20/70/31/7

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Cohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)Total
<=18 years26273727
Between 18 and 65 years0000000
>=65 years0000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)Total
Female13252417
Male13021310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)Total
Hispanic or Latino0102025
Not Hispanic or Latino25253522
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American14221414
White12052313
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Placebo (BW >=50 kg)Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)Cohort 2: Placebo (BW <50 kg)Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)Cohort 3: Placebo (BW 40 to 60 kg)Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)Total
United States26273727
08

Study locations

3 sites
  • Atlanta Center of Medical Research
    Atlanta, Georgia 30331 2012, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jan 2025, 23 months.

Results were first posted in Aug 2025, 7 months after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 23 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2023
First posted
Jan 25, 2023
StartActual
Feb 7, 2023
Primary completionActual
Jan 16, 2025
CompletionActual
Jan 16, 2025
Results first posted
Aug 26, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05696847
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Feb 7, 2023
Primary completion
Jan 16, 2025
Completion
Jan 16, 2025
Results posted
Aug 26, 2025
Last update
Aug 26, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion